Solid forms of an N-terminal domain androgen receptor inhibitor and uses thereof

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 11518747
APP PUB NO 20220259158A1
SERIAL NO

17732081

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to a crystalline form of Compound I, a salt, a solvate, or a solvate salt thereof or an amorphous form of Compound I, a salt, a solvate, or a solvate salt thereof. The present invention also provides compositions comprising the crystalline form and/or the amorphous form, therapeutic uses of the crystalline forms and/or the amorphous forms, and the compositions thereof.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ESSA PHARMA INC999 WEST BROADWAY SUITE 720 VANCOUVER BC V5Z 1K5

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Virsik, Peter Portola Valley, US 19 98
Zhou, Han-Jie Foster City, US 60 752

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Jun 6, 2026
7.5 Year Payment $3600.00 $1800.00 $900.00 Jun 6, 2030
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 6, 2034
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00